Total Payments
$17,506
2024 Payments
$729.79
Companies
37
Transactions
215
Medicare Patients
2,617
Medicare Billing
$247,799
Payment Breakdown by Category
Research$8,586 (49.0%)
Food & Beverage$3,538 (20.2%)
Consulting$2,700 (15.4%)
Other$1,558 (8.9%)
Travel$661.70 (3.8%)
Education$462.07 (2.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,586 | 5 | 49.0% |
| Food and Beverage | $3,538 | 188 | 20.2% |
| Consulting Fee | $2,700 | 1 | 15.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,558 | 2 | 8.9% |
| Travel and Lodging | $661.70 | 2 | 3.8% |
| Education | $462.07 | 17 | 2.6% |
Payments by Type
General
$8,920
210 transactions
Research
$8,586
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $13,232 | 14 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $522.73 | 30 | $0 (2023) |
| Eli Lilly and Company | $500.00 | 1 | $0 (2018) |
| Genentech USA, Inc. | $396.02 | 26 | $0 (2024) |
| PFIZER INC. | $392.79 | 30 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $296.91 | 12 | $0 (2024) |
| Janssen Biotech, Inc. | $288.68 | 12 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $199.73 | 5 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $170.42 | 12 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $151.53 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $729.79 | 31 | Janssen Biotech, Inc. ($107.18) |
| 2023 | $107.53 | 6 | PFIZER INC. ($83.58) |
| 2022 | $311.70 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($150.28) |
| 2021 | $160.72 | 8 | Alexion Pharmaceuticals, Inc. ($47.50) |
| 2020 | $163.34 | 10 | Novartis Pharmaceuticals Corporation ($35.12) |
| 2019 | $2,640 | 38 | Celgene Corporation ($2,096) |
| 2018 | $5,955 | 62 | Celgene Corporation ($4,572) |
| 2017 | $7,438 | 53 | Celgene Corporation ($6,487) |
All Payment Transactions
215 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: ONCOLOGY | ||||||
| 12/01/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $22.07 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $32.76 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Genentech USA, Inc. | Lunsumio (Biological), Polivy | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: BioOncology | ||||||
| 10/08/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $27.74 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/01/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Oncology | ||||||
| 09/03/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.20 | General |
| Category: Hematology | ||||||
| 08/27/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $21.66 | General |
| 08/26/2024 | Amgen Inc. | IMDELLTRA (AMG 757) (Biological) | Food and Beverage | In-kind items and services | $32.83 | General |
| Category: Hematology | ||||||
| 08/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $27.91 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $29.52 | General |
| Category: Oncology | ||||||
| 07/22/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: BioOncology | ||||||
| 07/17/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.38 | General |
| 06/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $32.33 | General |
| Category: Oncology | ||||||
| 06/11/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Food and Beverage | In-kind items and services | $74.29 | General |
| Category: Hematology | ||||||
| 05/21/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $24.98 | General |
| 05/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.09 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-4047-MM-014 - Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab | Celgene Corporation | $3,048 | 1 |
| CC-4047-MM-014 | Celgene Corporation | $2,976 | 1 |
| Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab (CC-4047-MM-014) | Celgene Corporation | $1,620 | 1 |
| A PHASE 2 STUDY OF LY2784544 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS | Eli Lilly and Company | $500.00 | 1 |
| CC-4047-MM-007 - Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $442.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 607 | 987 | $155,970 | $58,916 |
| 2022 | 9 | 615 | 1,018 | $159,994 | $59,901 |
| 2021 | 10 | 694 | 1,198 | $180,310 | $70,860 |
| 2020 | 10 | 701 | 1,168 | $176,723 | $58,122 |
Total Patients
2,617
Total Services
4,371
Medicare Billing
$247,799
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 162 | 365 | $62,860 | $24,337 | 38.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 208 | 288 | $32,108 | $11,952 | 37.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 60 | 152 | $17,480 | $9,205 | 52.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 49 | 49 | $13,965 | $4,610 | 33.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 66 | 66 | $13,332 | $3,389 | 25.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 29 | 29 | $11,745 | $2,886 | 24.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 23 | $3,775 | $2,096 | 55.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 13 | 15 | $705.00 | $442.20 | 62.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 153 | 353 | $60,716 | $23,665 | 39.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 208 | 289 | $32,079 | $12,182 | 38.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 58 | 168 | $19,320 | $8,640 | 44.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 74 | 74 | $14,948 | $4,008 | 26.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 43 | 43 | $12,255 | $4,006 | 32.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 36 | $5,904 | $2,696 | 45.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 18 | 23 | $5,750 | $2,520 | 43.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 21 | $8,505 | $1,847 | 21.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 11 | 11 | $517.00 | $336.81 | 65.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 160 | 370 | $63,640 | $25,424 | 39.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 244 | 347 | $38,517 | $16,112 | 41.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 86 | 254 | $29,210 | $13,182 | 45.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 41 | 41 | $11,685 | $4,025 | 34.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 57 | 57 | $11,514 | $3,314 | 28.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 32 | 32 | $12,105 | $3,002 | 24.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 32 | 43 | $7,052 | $2,779 | 39.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 15 | 17 | $4,250 | $1,944 | 45.8% |
About Dr. Donald Quick, MD
Dr. Donald Quick, MD is a Hematology & Oncology healthcare provider based in Lubbock, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316900020.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donald Quick, MD has received a total of $17,506 in payments from pharmaceutical and medical device companies, with $729.79 received in 2024. These payments were reported across 215 transactions from 37 companies. The most common payment nature is "" ($8,586).
As a Medicare-enrolled provider, Quick has provided services to 2,617 Medicare beneficiaries, totaling 4,371 services with total Medicare billing of $247,799. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Lubbock, TX
- Active Since 04/11/2006
- Last Updated 02/26/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1316900020
Products in Payments
- Pomalyst (Drug) $9,644
- Revlimid (Drug) $3,511
- GAZYVA (Biological) $196.81
- IMBRUVICA (Drug) $160.39
- KEYTRUDA (Biological) $144.26
- MEKINIST (Drug) $140.39
- OPDIVO (Biological) $127.76
- Imbruvica (Drug) $123.50
- EXKIVITY (Drug) $117.53
- TASIGNA (Drug) $114.74
- BOSULIF (Drug) $104.65
- XTANDI (Drug) $94.24
- ELIQUIS (Drug) $84.68
- ALTUVIIIO (Biological) $74.29
- Cresemba (Drug) $72.41
- ADCETRIS (Biological) $69.64
- PADCEV (Biological) $68.71
- EMPLICITI (Biological) $67.29
- AFINITOR (Drug) $65.18
- Avastin (Biological) $59.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lubbock
Muhammad Abid, M.d, M.D
Hematology & Oncology — Payments: $60,082
Hematology & Oncology $60,082
Nicholas Dcunha, Md, MD
Hematology & Oncology — Payments: $47,715
Hematology & Oncology $47,715
Dr. Davor Vugrin, Md, MD
Hematology & Oncology — Payments: $835.31
Hematology & Oncology $835.31
Victoria Dorr, Md, MD
Hematology & Oncology
Hematology & Oncology